The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy.

Michael RinkSabine RiethdorfHang YuMara KölkerMalte W VetterleinRoland DahlemMargit FischKlaus PantelArmin Soave

Published in: Journal of clinical medicine (2020)

The overall rate of VTE and CVE was low in our study. Presence of CTC was neither associated with an increased risk of VTE nor CVE in UCB patients treated with RC. According to this study, CTC are not a qualified biomarker for individualized thromboprophylaxis management in these patients.

Keyphrases

venous thromboembolism
circulating tumor cells
cardiovascular events
direct oral anticoagulants
end stage renal disease
newly diagnosed
circulating tumor
ejection fraction
type diabetes
prognostic factors
peritoneal dialysis